There are non-financial barriers that contribute to why a patient does not adhere to their medications, according to Andrea Baer, director of Patient Advocacy for Mended Hearts.
There are non-financial barriers that contribute to why a patient does not adhere to their medications, according to Andrea Baer, director of Patient Advocacy for Mended Hearts.
Transcript (slightly modified)
What barriers other than financial ones are there that prevent patients from being adherent to their medications?
Everybody always thinks of money as a barrier, but if you are looking at non-financial barriers—if there is a transportation issue if you are in a rural community and can’t get to a specialty pharmacy or a compounding pharmacy and you can’t get the drug. If you can’t access the information about the drugs or if you have side effects of the drugs and you don’t understand them and you don’t know who to talk to for it to be resolved, then you may just stop taking the medication.
So, it’s not just about financial barriers, I think that there a multitude of social, emotional, and economic reasons that people don’t adhere to their medication.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More